ICAM-1 overexpression counteracts immune-suppression by tumour cell-derived PGE2 to restore CTL function

  • Morgan D
N/ACitations
Citations of this article
11Readers
Mendeley users who have this article in their library.

Abstract

Tumour-infiltrating cytotoxic T lymphocytes (CTLs) play a key role in tumour killing. However, many cancers adopt various strategies to induce immunosuppression. Priming of naïve CD8 + T cells to become CTLs occurs via cognate interactions of the T cell receptor (TcR) and CD28 with tumour-derived peptide epitopes expressed on major histocompatibility complex (MHC) class I molecules and CD80/CD86 on T cells and antigen-presenting cells (APCs) respectively. Here we report that, in the absence of CD80/CD86 expression by renal carcinoma (Renca) cells, expression of intercellular adhesion molecule-1 (ICAM-1) by Renca cells provides a potent alternative co-stimulation to a tumour-specific CD8 + T cells causing them to produce interferon gamma (IFN-γ) which is crucial for the further up-regulation of ICAM-1 on tumour cells. We have shown that overexpression of cyclooxygenase-2 (COX-2), by Renca cells (Renca-T3), results in increased levels of prostaglandin (PG) E 2 production, which can directly suppress anti-tumour CD8 + T cells resulting in loss of CTL function in vivo and cause metastases to the tumor-draining lymph nodes (TDLNs). Significantly, our data also show that overexpression of ICAM-1 on Renca-T3 cells can counteract the immune-suppressive effect of PGE 2 and restore CTL responses.

Cite

CITATION STYLE

APA

Morgan, D. (2018). ICAM-1 overexpression counteracts immune-suppression by tumour cell-derived PGE2 to restore CTL function. Journal of Immunological Sciences, 2(1), 37–45. https://doi.org/10.29245/2578-3009/2018/1.1115

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free